Literature DB >> 25332995

Possible mechanisms of action of mushroom-derived glucans on inflammatory bowel disease and associated cancer.

Betty Schwartz1, Yitzhak Hadar1.   

Abstract

Since ancient times, medicinal mushrooms have been traditionally used as a health food or supplement for the prevention and cure of a range of health-statuses or diseases, such as overt inflammation, atherosclerosis, cancer, hypertension, diabetes and others. We concentrate in this review on the effect and putative mechanism of action of glucans harvested from fungi on inflammatory bowel disease (IBD) and colitis associated cancer. Many scientists including our own group have examined the immunomodulating effect of isolated polysaccharides-glucans in general and specifically in inflammation associated with cancer. In this manuscript we reviewed the sources, the chemical composition and medicinal properties of polysaccharides extracted from edible mushrooms. In addition we brought insights into their putative mechanisms of action behind each health-promoting activity of these interesting biomolecules. The preventive and therapeutic effects of the medicinal mushrooms and their components have been well documented in mouse and rat model systems and in cancer cell lines being the most striking effects reported to their anti-inflammatory and antitumor effect. Their anticancer effects were demonstrated mainly in in vitro and in vivo experimental systems but a very limited number of studies have been conducted in human populations. We can summarize that oral consumption of several mushrooms glucans is an efficient treatment to prevent colitis-associated dysplasias through modulation of mucosal inflammation and cell proliferation. Identifying new food-derived isolates and understanding their mechanisms of action are the main challenges in using mushrooms glucans for therapeutic purposes in the field of IBD and associated cancer. Only an in-depth understanding of the mechanism of action and cross-talk between the inflammatory cell, epithelial cell and fungi derived glucans on which we have a based structural knowledge will lead to well designed intervention clinical human studies to test the efficacy of these molecules on intestinal inflammation and colitis associated cancer.

Entities:  

Keywords:  colon cancer; inflammation; inflammatory bowel disease (IBD); α-glucans; β-glucans

Year:  2014        PMID: 25332995      PMCID: PMC4202469          DOI: 10.3978/j.issn.2305-5839.2014.01.03

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN: 2305-5839


  82 in total

Review 1.  Collaboration between the innate immune receptors dectin-1, TLRs, and Nods.

Authors:  David M Underhill
Journal:  Immunol Rev       Date:  2007-10       Impact factor: 12.988

2.  Efficacy of oral administered superfine dispersed lentinan for advanced pancreatic cancer.

Authors:  Kyoko Shimizu; Shinya Watanabe; Seiji Watanabe; Kenji Matsuda; Tetsuya Suga; Saburo Nakazawa; Keiko Shiratori
Journal:  Hepatogastroenterology       Date:  2009 Jan-Feb

3.  National estimates of the burden of inflammatory bowel disease among racial and ethnic groups in the United States.

Authors:  Geoffrey C Nguyen; Christopher A Chong; Rachel Y Chong
Journal:  J Crohns Colitis       Date:  2013-09-24       Impact factor: 9.071

Review 4.  Natural and modified (1-->3)-beta-D-glucans in health promotion and disease alleviation.

Authors:  Djordje B Zeković; Stefan Kwiatkowski; Miroslav M Vrvić; Dragica Jakovljević; Colm A Moran
Journal:  Crit Rev Biotechnol       Date:  2005 Oct-Dec       Impact factor: 8.429

Review 5.  Beta-glucan recognition by the innate immune system.

Authors:  Helen S Goodridge; Andrea J Wolf; David M Underhill
Journal:  Immunol Rev       Date:  2009-07       Impact factor: 12.988

6.  Clinical efficacy of superfine dispersed lentinan (beta-1,3-glucan) in patients with hepatocellular carcinoma.

Authors:  Norio Isoda; Yuichiro Eguchi; Haruhiko Nukaya; Keiko Hosho; Yasuyo Suga; Tetsuya Suga; Saburo Nakazawa; Kentaro Sugano
Journal:  Hepatogastroenterology       Date:  2009 Mar-Apr

7.  Beta-glucan attenuates inflammatory cytokine release and prevents acute lung injury in an experimental model of sepsis.

Authors:  Abdulkadir Bedirli; Mustafa Kerem; Hatice Pasaoglu; Nalan Akyurek; Tugan Tezcaner; Sehri Elbeg; Leyla Memis; Omer Sakrak
Journal:  Shock       Date:  2007-04       Impact factor: 3.454

8.  Ligands for the beta-glucan receptor, Dectin-1, assigned using "designer" microarrays of oligosaccharide probes (neoglycolipids) generated from glucan polysaccharides.

Authors:  Angelina S Palma; Ten Feizi; Yibing Zhang; Mark S Stoll; Alexander M Lawson; Esther Díaz-Rodríguez; María Asunción Campanero-Rhodes; Júlia Costa; Siamon Gordon; Gordon D Brown; Wengang Chai
Journal:  J Biol Chem       Date:  2005-12-21       Impact factor: 5.157

9.  Experimental evaluation of analgesic and anti-inflammatory potential of Oyster mushroom Pleurotus florida.

Authors:  Aditya Ganeshpurkar; Gopal Rai
Journal:  Indian J Pharmacol       Date:  2013 Jan-Feb       Impact factor: 1.200

Review 10.  The effects of beta-glucan on human immune and cancer cells.

Authors:  Godfrey Chi-Fung Chan; Wing Keung Chan; Daniel Man-Yuen Sze
Journal:  J Hematol Oncol       Date:  2009-06-10       Impact factor: 17.388

View more
  12 in total

1.  Particulate β-glucan regulates the immunosuppression of granulocytic myeloid-derived suppressor cells by inhibiting NFIA expression.

Authors:  Xinyu Tian; Jie Tian; Xinyi Tang; Ke Rui; Yue Zhang; Jie Ma; Yungang Wang; Huaxi Xu; Liwei Lu; Shengjun Wang
Journal:  Oncoimmunology       Date:  2015-07-01       Impact factor: 8.110

Review 2.  Beta-glucan contamination of pharmaceutical products: How much should we accept?

Authors:  Claire Barton; Kim Vigor; Robert Scott; Paul Jones; Heike Lentfer; Heather J Bax; Debra H Josephs; Sophia N Karagiannis; James F Spicer
Journal:  Cancer Immunol Immunother       Date:  2016-07-29       Impact factor: 6.968

Review 3.  Effects of Non-Starch Polysaccharides on Inflammatory Bowel Disease.

Authors:  Ying Nie; Qinlu Lin; Feijun Luo
Journal:  Int J Mol Sci       Date:  2017-06-27       Impact factor: 5.923

Review 4.  Mushroom Polysaccharides: Chemistry and Antiobesity, Antidiabetes, Anticancer, and Antibiotic Properties in Cells, Rodents, and Humans.

Authors:  Mendel Friedman
Journal:  Foods       Date:  2016-11-29

Review 5.  B-glucans from Grifola frondosa and Ganoderma lucidum in breast cancer: an example of complementary and integrative medicine.

Authors:  Paola Rossi; Raffaele Difrancia; Vincenzo Quagliariello; Elena Savino; Paolo Tralongo; Cinzia Lucia Randazzo; Massimiliano Berretta
Journal:  Oncotarget       Date:  2018-05-15

6.  The Effect of Dietary Mushroom Agaricus bisporus on Intestinal Microbiota Composition and Host Immunological Function.

Authors:  Gloria I Solano-Aguilar; Saebyeol Jang; Sukla Lakshman; Richi Gupta; Ethiopia Beshah; Masoumeh Sikaroodi; Bryan Vinyard; Aleksey Molokin; Patrick M Gillevet; Joseph F Urban
Journal:  Nutrients       Date:  2018-11-09       Impact factor: 5.717

Review 7.  Beta-Glucans from Fungi: Biological and Health-Promoting Potential in the COVID-19 Pandemic Era.

Authors:  Iwona Mirończuk-Chodakowska; Karolina Kujawowicz; Anna Maria Witkowska
Journal:  Nutrients       Date:  2021-11-06       Impact factor: 5.717

8.  Lentinula edodes β-glucan enriched diet induces pro- and anti-inflammatory macrophages in rabbit.

Authors:  Helena Crespo; Hugo Guillén; Lorena de Pablo-Maiso; Carmen Gómez-Arrebola; Gregorio Rodríguez; Idoia Glaria; Damián de Andrés; Ramsés Reina
Journal:  Food Nutr Res       Date:  2017-12-12       Impact factor: 3.894

Review 9.  Effects of Medicinal Fungi-Derived β-Glucan on Tumor Progression.

Authors:  Vaclav Vetvicka; Tamara V Teplyakova; Alexandra B Shintyapina; Tatiana A Korolenko
Journal:  J Fungi (Basel)       Date:  2021-03-25

Review 10.  Antioxidant Activity of Mushroom Extracts/Polysaccharides-Their Antiviral Properties and Plausible AntiCOVID-19 Properties.

Authors:  Sechul Chun; Judy Gopal; Manikandan Muthu
Journal:  Antioxidants (Basel)       Date:  2021-11-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.